

Medlab Clinical Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Medlab Clinical Limited
ABN:	51 169 149 071
Reporting period:	For the year ended 30 June 2023
Previous period:	For the year ended 30 June 2022

2. Results for announcement to the market

			\$
Revenues from ordinary activities	down	76.5% to	892,081
Loss from ordinary activities after tax attributable to the owners of Medlab Clinical Limited	down	5.4% to	(6,778,367)
Loss for the year attributable to the owners of Medlab Clinical Limited	down	5.4% to	(6,778,367)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the Consolidated Entity after providing for income tax and non-controlling interest amounted to \$6,778,367 (30 June 2022: \$7,162,433).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	56.06	341.62

The net tangible assets at 30 June 2022 has been adjusted for the effect of the share consolidation on 5 August 2022.

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Australian Accounting Standards are utilised when compiling the financial report.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unmodified opinion (with material uncertainty on going concern) has been issued.

11. Attachments

Details of attachments (if any):

The Annual Report of Medlab Clinical Limited for the year ended 30 June 2023 is attached.

12. Signed

Signed

_____

Date: 23 April 2024

Medlab Clinical Limited

ABN 51 169 149 071

Annual Report - 30 June 2023

Medlab Clinical Limited
Directors' report
30 June 2023

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Consolidated Entity') consisting of Medlab Clinical Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2023.

Directors

The following persons were directors of Medlab Clinical Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Current

Matthew Hudson - Non-Executive Chairman (appointed a Non-Executive Director on 6 March 2023, and Non-Executive Chairman on 25 March 2024)

Edmond Tan - Non-Executive Director (appointed 25 March 2024)

Tim Walker - Non-Executive Director (appointed 25 March 2024)

Former

Sean Hall - Chairman (Chairman from 6 March 2023 and Chief Executive Officer on a part-time contractual basis from 1 Sept 2023, and resigned 25 March 2024)

Michael Hall - Non-Executive Chairman (resigned 6 March 2023)

Laurence McAllister - Non-Executive Director (resigned 31 August 2022)

Drew Townsend - Non-Executive Director (resigned 26 February 2023)

Cheryl Maley - Non-Executive Director (resigned 26 February 2023)

Mohit Gupta - Non-Executive Director (appointed 8 August 2022 and resigned 13 March 2023)

Michael Carter - Non-Executive Director (appointed 13 March 2023 and resigned 25 March 2024)

Principal activities

The Company is an Australian biotechnology company that specialises in the application of NanoCelle® drug delivery technology to existing and new pharmaceuticals - with the aim of empowering patients with chronic diseases and mental health conditions and enhancing their lives.

On 27 February 2023, the ASX suspended trading of the Company's shares. Subsequently, Hall Chadwick was engaged as external consultants to assist the directors of the Company with an informal workout and restructure of the Company's financial affairs.

The Company is currently operating in a care and maintenance capacity whilst the Directors devise and implement a corporate restructure plan. The Company has retrenched most of its workforce and is currently operating with skeleton staff for the purpose of the restructure.

The restructuring process will involve dealing with current and new investors, as well as any interested parties to achieve the ongoing success and future of the Company which will ensure the best outcome for all stakeholders.

Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Review of operations

The Consolidated Entity incurred a loss after tax from continuing operations as set out below:

	Consolidated	
	2023	2022
	\$	\$
Loss after income tax expense from continuing operations	(6,433,297)	(8,388,452)
Profit/(loss) after income tax expense from discontinued operations	-	1,159,638
Loss after income tax expense for the year	<u>(6,433,297)</u>	<u>(7,228,814)</u>

At year end, the Consolidated Entity had total assets of \$3,144,178 (2022: 11,366,603) and total liabilities of \$1,864,130 (2022: \$3,617,466).

Medlab Clinical Limited
Directors' report
30 June 2023

Hall Chadwick was engaged as external consultants in March 2023 to assist the directors of the Company with an informal workout and restructure of the Company's financial affairs. The Company is currently operating in a care and maintenance capacity whilst the Directors devise and implement a corporate restructure plan. The Company has retrenched most of its workforce and is currently operating with skeleton staff for the purpose of the restructure.

Significant changes in the state of affairs

On 5 August 2022, the Company completed the consolidation of its share capital on a 150 to 1 basis (refer note 20). The consolidation was approved by the Company's shareholders at an extraordinary meeting of shareholders held on 28 July 2022.

As noted under Principal Activities, on 27 February 2023, the ASX suspended trading of the Company's shares. Subsequently, Hall Chadwick was engaged as external consultants to assist the directors of the Company with the identification and completion of a corporate transaction that restructure the Company's affairs. On 27 February 2023, the Company retrenched the majority of its workforce and shifted its operations into a care and maintenance capacity, whilst the Directors sought to devise and implement a corporate restructure plan.

As announced to the market on 21 March 2023, 7 June 2023, 3 August 2023, 12 September 2023, and 9 November 2023, the Company conducted a significant campaign to identify a corporate transaction to recapitalise the business, restructure the operations, or sell the assets.

As outlined in the announcements dated 9 November 2023 and 22 November 2023, the Company announced a proposed restructure transaction that would result in a licence agreement for its NanoCelle intellectual property to an unrelated party, sale of 100% of the issued share capital in Medlab IP Pty Ltd and Medlab Clinical Inc. to Dr Sean Hall (see *Matters subsequent to the end of financial year* section), and a subsequent capital raising to explore new business opportunities.

As at the date of this report, the Company is continuing to consider new business opportunities and anticipates it will provide the market with a further update upon the execution of a binding agreement.

With exception to those above, there were no other significant changes in the state of affairs of the Consolidated Entity during the financial year.

Material business risks

The main risk for the Company is the going concern matter, as the capacity for the Company to raise adequate capital to continue to fund operations, was not successful and did not eventuate.

To this end, the Company decided to suspend trading on the ASX, and the operations were discontinued. The Company entered into an agreement with Hall Chadwick, to act as consultants, to support the Company through a corporate restructuring process.

The Company (as announced to the market), has issued a notice of extraordinary meeting, for shareholders to vote on future position of the Company. Further details provided in the subsequent events paragraph.

Matters subsequent to the end of the financial year

On 12 January 2024, the Company completed the sale of 100% of the issued share capital in Medlab IP Pty Ltd and Medlab Clinical US Inc., from its wholly owned subsidiary Medlab Pty Ltd to Dr. Sean Hall. In consideration for the disposal, Dr. Sean Hall (or his associated entity) agrees to pay the Entitled Shareholders, a 20% royalty for a period of 4 years commencing on the date of settlement of the sale agreement. The Entitled Shareholders are those shareholders of Medlab Limited as determined at the date of settlement.

Likely developments and expected results of operations

As outlined in the *Significant changes to the state of affairs* section, the Company is continuing to investigate new business opportunities and anticipates that upon execution of a binding agreement, it will complete a capital raise to progress this opportunity.

Environmental regulation

The Consolidated Entity is not subject to any significant environmental regulation under Australian Commonwealth or State law.

Medlab Clinical Limited
Directors' report
30 June 2023

Information on directors

Name:	Matthew Hudson (appointed a Non-Executive Director on 6 March 2023, and Non-Executive Chairman on 25 March 2024)
Title:	Non-Executive Chairman
Qualifications:	BCom
Experience and expertise:	Mr Hudson has extensive experience raising capital for projects based in Africa, Latin America, and Asia. He is a former Credit Suisse and Arthur Andersen advisor, who is now the Co-Founder and Managing Director of Hudson Koch Energy, which operates 43 oil and gas wells across Kansas and Oklahoma. He is also the Founder and Managing Director of United Minerals which operated the historic Potosi Mine in Chihuahua, Mexico.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Chairman
Interests in shares:	Nil
Interests in options:	Nil
Name:	Edmond Tan (appointed 25 March 2024)
Title:	Non-Executive Director
Qualifications:	BCom
Experience and expertise:	Mr Tan is a financial services professional with over 10 years' experience in various roles which include Private Wealth Management, Family Office, and Structured Finance. In addition, he was involved in the establishment of a mid-market private equity joint venture fund with a specific focus on foreign investment into Australia. Currently, Mr Tan is a Director of Regenerate Pty Ltd a rare earth magnet recycling technology based in Houston, Texas. He is also the Australian Representative for Obsidian Global Partners LLC, a structured financier for ASX listed companies.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	None
Interests in shares:	Nil
Interests in options:	Nil
Name:	Tim Walker (appointed 25 March 2024)
Title:	Non-Executive Director
Qualifications:	BCom
Experience and expertise:	Mr Walker is a corporate finance professional with extensive experience in originating, managing, and leading a variety resource-focused transaction. Specifically, specialising in M&A transactions across the Canadian and Australian markets, IPOs, and both equity and debt financing solutions. Tim's past directorships with exploration companies have provided him with a breadth of experience across various commodity groups, including lithium exploration, rare earth and niobium hosted carbonatite deposits, whilst also having experience transacting on iron ore and base metal projects.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	None
Interests in shares:	Nil
Interests in options:	Nil

Medlab Clinical Limited
Directors' report
30 June 2023

Name:	Sean Hall (Chairman from 6 March 2023 and Chief Executive Officer on a part-time contractual basis from 1 Sept 2023, and resigned 25 March 2024)
Title:	Executive Chairman
Qualifications:	MD, MBA (Clin Pharm Mtg)
Experience and expertise:	Dr Hall has over 20 years experience in the Australian Healthcare and food industries and early phase drug discovery in Australia and Asia. Sean is best known for building Australia's leading practitioner brand, BioCeuticals. Dr Hall is an active member of Medicines Australia, American Federation for Medical Research, American Academy of Anti-Ageing Medicine, Ausbiotech, a member of the Scientific Advisory Board for BITs Life Science China and a Board Member of the International Probiotics Association. Dr Hall has completed Executive Education at Harvard Graduate School of Business and more recently continuing Medical Education through Harvard Medical School.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Executive Chairman and member of the Nomination and Remuneration Committee
Interests in shares:	392,373
Interests in options:	Nil
Name:	Michael Carter (appointed 13 March 2023 and resigned 25 March 2024)
Title:	Non-Executive Director
Qualifications:	BCom, GradDipAppFin
Experience and expertise:	Mr Michael Carter graduated from the University of Western Australia in 1998 with a Bachelor of Commerce, majoring in accounting and finance. Mr Carter also completed a graduate diploma in Applied Finance and Investment at FINSIA in 2002. Mr Carter is experienced in structuring corporate transactions and has also worked in ongoing corporate advisory roles with numerous ASX listed entities over the last 18 years. Mr Carter has been employed as a stockbroker since 1999 and was previously a director of Indian Ocean Capital. He is currently an associate director of CPS Capital Group and Non-Executive Director of European Lithium Limited.
Other current directorships:	European Lithium Limited (since 31 August 2021)
Former directorships (last 3 years):	None
Special responsibilities:	None
Interests in shares:	Nil
Interests in options:	Nil

Medlab Clinical Limited
Directors' report
30 June 2023

Name:	Laurence McAllister (resigned 31 August 2022)
Title:	Non-Executive Director (Executive Director until 30 April 2022 and Non-Executive Director thereafter)
Experience and expertise:	Mr McAllister is an experienced senior executive with strong consumer & healthcare experience with senior international tenure with the Coca-Cola Company, Sanofi Pharmaceuticals, McPhersons and now Medlab Biotech. With dynamic multi-functional experience across 82 Countries domestically and as an expat for 12 years around the world, Mr McAllister's most recent position was the CEO & Managing Director of McPherson's (ASX), a leading supplier of health, wellness, beauty, household, and personal care across global markets. Prior to this, Mr McAllister ran the Sanofi affiliate as Managing Director, overseeing all 5 business units with a turnover of \$1.1B AUD and was simultaneously on the Board of Medicines Australia to engage the interaction with the TGA and PBS on behalf of the pharmaceutical industry within the Clinical & Medical agenda for Australian patients' welfare. Prior to this, he worked for over 23 years with the Coca-Cola Company, managing Sales & Marketing, New Product Development, M&A, Innovation and the Research and Development function across Europe, Eurasia, and the Middle East across 72 Countries. Mr McAllister was also the President of the Nordics Division and the EVP and Chief Commercial, Customer & Marketing Officer for The Japan Coca-Cola Company. Throughout his business tenure, Mr McAllister has represented diverse Industry / Category / Company Boards in Germany, Sweden, Norway, Denmark and Finland, Great Britain, Japan and 3 Australian based Companies (being 2 x ASX listed, and one community/sports & health-based entities)
Other current directorships:	Director of McPherson's Limited until 9 December 2020
Former directorships (last 3 years):	None
Special responsibilities:	Member of the Risk Management and Audit Committee, and Nomination Remuneration Committee
Interests in shares:	Nil*
Interests in options:	Nil*
Name:	Michael Hall (resigned 6 March 2023)
Title:	Non-Executive Chairman
Qualifications:	B.Com, CPA
Experience and expertise:	Mr Hall has a long history in the management and building of successful nutrition companies. Mr Hall's early career was in accounting, retailing and private banking.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Member of the Risk Management and Audit Committee, member of the Nomination and Remuneration Committee and Chairman of the Board of Directors
Interests in shares:	106,049*
Interests in options:	Nil*
Name:	Drew Townsend (resigned 26 February 2023)
Title:	Non-Executive Director
Qualifications:	B.Com, CA,, MAICD
Experience and expertise:	Mr Townsend is a senior partner in the chartered accounting firm of Hall Chadwick and has been a partner in this firm for over 25 years. He is an experienced chartered accountant and corporate advisor to numerous SMEs.
Other current directorships:	Non-Executive Chairman of Qantum Health Group Limited
Former directorships (last 3 years):	None
Special responsibilities:	Chairman of the Risk Management and Audit Committee, and Nomination and Remuneration Committee
Interests in shares:	107,570*
Interests in options:	Nil*

Medlab Clinical Limited
Directors' report
30 June 2023

Name: Cheryl Maley (resigned 26 February 2023)
Title: Non-Executive Director
Qualifications: BSc, MBA, AICD
Experience and expertise: Ms Maley is currently a Managing Director of Oncology for global healthcare company Novartis (Australia and New Zealand). Ms Maley has strong pharmaceutical experience including over 20 years in roles across Sales, Marketing, Business Development, Commercial Excellence, Patient Access and General Management. Cheryl is also a former director of Riding for the Disabled, ending 31 July 2021. Ms Maley is a knowledgeable and multi-functional leader with a proven track record in accelerating and driving long-term strategic growth through innovation, partnering and steering organisational development and projects. Ms Maley has a Bachelor of Science Degree, a Diploma of Education, a Masters of Business Administration and is a Graduate of the Australian Institute of Company Directors. She has a passion for innovation and has completed formal innovation training with What-If Innovation (UK), Kellogg Institute (USA), Inventium (Australia) and RAW Innovation (Australia).
Other current directorships: None
Former directorships (last 3 years): None
Special responsibilities: None
Interests in shares: Nil*
Interests in options: 10,000*

Name: Mohit Gupta (appointed 8 August 2022 and resigned 13 March 2023)
Title: Non-Executive Director
Qualifications: BCom, MBA
Experience and expertise: Mr Gupta is a seasoned professional with more than 20 years in various roles and geographies, with the last 10 years in Pharma in various capacities based in Australia and Switzerland. Mr Gupta previously worked in supply chain, projects and procurement and has experience in large deals for acquisition and divestments. He has led teams for various projects with conflicting priorities and timelines to achieve the goals.
Other current directorships: None
Former directorships (last 3 years): None
Special responsibilities: None
Interests in shares: Nil*
Interests in options: Nil*

'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

* Interests in the shares and options of the Company as at the date of resignation as a director.

Company secretary

The company secretary is Mr Kerem Kaya BCom, CPA. Mr Kaya has extensive pharmaceutical industry and financial experience gained at one of the world's largest pharmaceutical companies, Novartis.

Meetings of directors

The number of meetings of the Company's Board of Directors ('the Board') held during the year ended 30 June 2023, and the number of meetings attended by each director were:

	Full Board		Nomination and Remuneration Committee		Risk Management and Audit Committee	
	Attended	Held	Attended	Held	Attended	Held
Sean Hall	21	21	-	-	-	-
Matthew Hudson ^(a)	14	14	-	-	-	-
Michael Carter ^(a)	14	14	-	-	-	-
Michael Hall ^(b)	7	7	-	-	1	1
Drew Townsend ^(c)	6	6	-	-	1	1
Cheryl Maley ^(c)	6	6	-	-	-	-
Mohit Gupta ^(d)	5	6	-	-	-	-
Laurence McAllister ^(e)	1	1	-	-	-	-

(a) Matthew Hudson and Michael Carter were appointed on 6 March 2023 and 13 March 2023 respectively.

(b) Michael Hall resigned on 6 March 2023.

(c) Drew Townsend and Cheryl Maley resigned on 26 February 2023.

(d) Mohit Gupta was appointed on 8 August 2022 and resigned on 13 March 2023.

(e) Laurence McAllister resigned on 31 August 2022.

Held: represents the number of meetings held during the time the director held office.

During the year the Board as part of its role has undertaken the responsibilities of the Nomination and Remuneration Committee and carried out the functions set out in the committee's charter to ensure that its objectives are met.

Remuneration report (audited)

The remuneration report details the key management personnel remuneration arrangements for the Consolidated Entity, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including all directors.

The remuneration report is set out under the following main headings:

- Principles used to determine the nature and amount of remuneration
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional information
- Additional disclosures relating to key management personnel

Principles used to determine the nature and amount of remuneration

The objective of the Consolidated Entity's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:

- competitiveness and reasonableness
- acceptability to shareholders
- performance linkage / alignment of executive compensation
- transparency

The Nomination and Remuneration Committee is responsible for determining and reviewing remuneration arrangements for its directors and executives. This function was performed by the Board in 2023. The performance of the Consolidated Entity depends on the quality of its directors and executives. The remuneration philosophy is to attract, motivate and retain high performance and high quality personnel.

Medlab Clinical Limited
Directors' report
30 June 2023

The Nomination and Remuneration Committee has structured an executive remuneration framework that is market competitive and complementary to the reward strategy of the consolidated entity.

Alignment to shareholders' interests:

- Has economic profit as a core component of plan design
- Focuses on sustained growth in shareholder wealth, consisting of dividends and growth in share price, and delivering constant or increasing return on assets as well as focusing the executive on key non-financial drivers of value
- Attracts and retains high calibre executives

Alignment to program participants' interests:

- Rewards capability and experience
- Reflects competitive reward for contribution to growth in shareholder wealth
- Provides a clear structure for earning rewards

In accordance with best practice corporate governance, the structure of non-executive director and executive director remuneration is separate.

Non-executive directors remuneration

Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive directors' fees and payments are reviewed annually by the Nomination and Remuneration Committee. The Nomination and Remuneration Committee may, from time to time, receive advice from independent remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market. The chairman's fees are determined independently to the fees of other non-executive directors based on comparative roles in the external market. The chairman is not present at any discussions relating to the determination of his own remuneration.

ASX listing rules require the aggregate non-executive directors' remuneration be determined periodically by a general meeting. The most recent determination was at the Annual General Meeting held on 16 October 2020, where the shareholders approved a maximum annual aggregate remuneration of \$600,000

Executive remuneration

The Consolidated Entity aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.

The executive remuneration and reward framework has four components:

- Base pay and non-monetary benefits
- Short-term performance incentives
- Share-based payments
- Other remuneration such as superannuation and long service leave

The combination of these comprises the executive's total remuneration.

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed annually by the Nomination and Remuneration Committee based on individual and business unit performance, the overall performance of the Consolidated Entity and comparable market remunerations.

Executives may receive their fixed remuneration in the form of cash or other fringe benefits (for example motor vehicle benefits) where it does not create any additional costs to the Consolidated Entity and provides additional value to the executive.

The long-term incentives ('LIT') include long service leave and share-based payments. Shares are awarded to executives under the shareholder approved Employee Share Option Plan (ESOP) based on long-term incentive measures. These include increase in shareholders value relative to the entire market and the increase compared to the consolidated entity's direct competitors. On 12 November 2020, the Company granted 12,000,000 unlisted options under the ESOP to the following Directors for nil consideration: Michael Hall, Drew Townsend, Sean Hall and Laurence McAllister. The options vested on 31 January 2021 and expired, unexercised, on 31 October 2022. The value of the options at grant date was \$580,000.

Medlab Clinical Limited
Directors' report
30 June 2023

Consolidated entity performance and link to remuneration

The Company aims to align its executive remuneration to its strategic and business objective and the creation of shareholder wealth. Refer to the section 'Additional information' below for measures of the Consolidated Entity's financial performance over the last five years. These measures are not necessarily consistent with the measures used in determining the variable amounts of remuneration to be awarded to key management personnel. As a consequence, there may not always be a direct correlation between the key performance measures and the variable remuneration awarded.

Use of remuneration consultants

The Consolidated Entity did not engage remuneration consultants to prepare a formal remuneration report during the financial year ended 30 June 2023.

Voting and comments made at the Company's 30 September 2022 Annual General Meeting ('AGM')

At the 30 September 2022 AGM, 93.76% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2022. The Company did not receive any specific feedback at the AGM regarding its remuneration practices.

Details of remuneration

Amounts of remuneration

Details of the remuneration of key management personnel of the Consolidated Entity are set out in the following tables.

The key management personnel of the Consolidated Entity consisted of the following directors of Medlab Clinical Limited:

- Sean Hall - Chairman, Managing Director and Chief Executive Officer
- Matthew Hudson - Non-Executive Director (appointed 6 March 2023)
- Michael Carter - Non-Executive Director (appointed 13 March 2023)
- Laurence McAllister - Non-Executive Director (resigned 31 August 2022)
- Michael Hall - Non-Executive Chairman (resigned 6 March 2023)
- Drew Townsend - Non-Executive Director (resigned 26 February 2023)
- Cheryl Maley - Non-Executive Director (resigned 26 February 2023)
- Mohit Gupta - Non-Executive Director (appointed 8 August 2022 and resigned 13 March 2023)

And the following persons:

- Kerem Kaya - Chief Financial Officer, Company Secretary and Chief Operations Officer
- Dr Jeremy Henson (Director of Medical Research) (appointed 19 July 2022 and made redundant 2 March 2023)
- Dr Luis Vitetta - Director of Medical Research (resigned 20 July 2022)
- Dr David Rutolo - Director of Science (made redundant 30 June 2023)
- Ian Curtin Smith - Chief Information Officer (made redundant 2 March 2023)

Medlab Clinical Limited
Directors' report
30 June 2023

	Short-term benefits			Post-employment benefits	Non-cash Long-term benefits	Non-cash Share-based payments		
	Cash salary and fees	Cash in lieu of leave	Bonus	Super-annuation	Long service leave	Equity-settled ⁽ⁱ⁾	Termination benefits	Total
2023	\$	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>								
Michael Carter ^(a)	19,783	-	-	-	-	-	-	19,783
Matthew Hudson ^(a)	20,000	-	-	-	-	-	-	20,000
Michael Hall ^(b)	115,385	-	-	6,865	-	-	-	122,250
Drew Townsend ^(c)	-	-	-	-	-	-	-	-
Cheryl Maley ^(c)	44,200	-	-	-	-	-	-	44,200
Mohit Gupta ^(d)	39,826	-	-	-	-	-	-	39,826
Laurence McAllister ^(e)	11,050	-	-	-	-	-	-	11,050
<i>Executive Directors:</i>								
Sean Hall	415,192	-	-	43,595	7,079	-	-	465,866
<i>Other Key Management Personnel:</i>								
Kerem Kaya	250,447	-	-	26,285	-	-	-	276,732
Jeremy Henson ^(f)	196,071	-	-	19,128	-	-	38,501	253,700
Luis Vitetta ^(g)	68,849	-	-	1,562	-	-	-	70,411
David Rutolo ^(h)	178,244	-	-	13,636	-	-	-	191,880
Ian Curtin Smith ^(h)	181,570	-	30,000	18,161	-	-	27,596	257,327
	<u>1,540,617</u>	<u>-</u>	<u>30,000</u>	<u>129,232</u>	<u>7,079</u>	<u>-</u>	<u>66,097</u>	<u>1,773,025</u>

(a) Matthew Hudson and Michael Carter were appointed on 6 March 2023 and 13 March 2023 respectively.

(b) Michael Hall resigned on 6 March 2023.

(c) Drew Townsend and Cheryl Maley resigned on 26 February 2023.

(d) Mohit Gupta was appointed on 8 August 2022 and resigned on 13 March 2023.

(e) Laurence McAllister resigned on 31 August 2022.

(f) Jeremy Henson was appointed Director of Medical Research on 19 July 2022 and was made redundant on 2 March 2023.

(g) Luis Vitetta resigned on 20 July 2022.

(h) Ian Curtin Smith and David Rutolo were made redundant on 2 March 2023 and 30 June 2023 respectively.

(i) The amounts included in the share-based remuneration represent the grant date fair value of performance rights and options, amortised on a straight-line basis over the expected vesting period.

Medlab Clinical Limited
Directors' report
30 June 2023

	Short-term benefits			Post-employment benefits	Non-cash Long-term benefits	Non-cash Share-based payments		
	Cash salary and fees	Cash in lieu of leave	Bonus	Super-annuation	Long service leave	Equity-settled ^(b)	Termination benefits	Total
2022	\$	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>								
Michael Hall	176,923	-	-	10,192	-	-	-	187,115
Drew Townsend	66,000	-	-	-	-	-	-	66,000
Cheryl Maley	66,000	-	-	-	-	179,805	-	245,805
Laurence McAllister ^(a)	66,000	-	-	-	-	-	-	66,000
<i>Executive Directors:</i>								
Laurence McAllister ^(a)	554,500	-	-	-	-	-	-	554,500
Sean Hall	441,346	68,826	-	51,017	14,921	-	-	576,110
<i>Other Key Management Personnel:</i>								
Kerem Kaya	262,260	-	-	26,226	4,343	-	-	292,829
Luis Vitetta	297,003	-	-	29,581	11,638	-	-	338,222
David Rutolo	173,913	-	-	13,527	-	-	-	187,440
Ian Curtin Smith	209,808	-	-	20,981	3,632	-	-	234,421
	<u>2,313,753</u>	<u>68,826</u>	<u>-</u>	<u>151,524</u>	<u>34,534</u>	<u>179,805</u>	<u>-</u>	<u>2,748,442</u>

(a) Laurence McAllister was an Executive Director until 30 April 2022 and a Non-Executive Director thereafter.

(b) The amounts included in the share-based remuneration represent the grant date fair value of performance rights and options, amortised on a straight-line basis over the expected vesting period.

Note: During the financial year ended 30 June 2022, there were 27 fortnightly pay periods.

Medlab Clinical Limited
Directors' report
30 June 2023

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration		At risk - STI		At risk - LTI	
	2023	2022	2023	2022	2023	2022
<i>Non-Executive Directors:</i>						
Michael Carter	100%	-	-	-	-	-
Matthew Hudson	100%	-	-	-	-	-
Michael Hall	100%	100%	-	-	-	-
Drew Townsend	100%	100%	-	-	-	-
Mohit Gupta	100%	-	-	-	-	-
Cheryl Maley	100%	27%	-	-	-	73%
Laurence McAllister	100%	100%	-	-	-	-
<i>Executive Directors:</i>						
Laurence McAllister	-	100%	-	-	-	-
Sean Hall	100%	100%	-	-	-	-
<i>Other Key Management Personnel:</i>						
Kerem Kaya	100%	100%	-	-	-	-
Jeremy Henson	100%	-	-	-	-	-
Luis Vitetta	100%	100%	-	-	-	-
David Rutolo	100%	100%	-	-	-	-
Ian CurtinSmith	100%	100%	-	-	-	-

Service agreements

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name: Sean Hall
Title: Managing Director and Chief Executive Officer
Agreement commenced: 1 July 2012
Term of agreement: No fixed term
Details: Base salary (plus super) increased to \$425,000 on 21 June 2021. Base salary is reviewed annually by the Nomination and Remuneration Committee. 12 month termination notice by either party, non-solicitation and non-compete clauses. As of 22 May 2023, a Temporary Variation to Terms and Conditions of Employment was signed reducing working hours from 76 hours per fortnight to 60.80 hours per fortnight reducing the fortnightly remuneration accordingly.

Name: Kerem Kaya
Title: Chief Financial Officer and Company Secretary
Agreement commenced: 13 May 2021
Term of agreement: No fixed term
Details: Base annual salary increased in February 2022 from \$250,000 to \$256,250 plus superannuation. Base salary to be reviewed annually by the Nomination and Remuneration Committee. 4 weeks termination notice by either party, eligible to be part of the consolidated entity's ESOP. As of 22 May 2023, a Temporary Variation to Terms and Conditions of Employment was signed reducing working hours from 76 hours per fortnight to 60.80 hours per fortnight reducing the fortnightly remuneration accordingly.

Name: Jeremy Henson
Title: Director of Medical Research
Agreement commenced: 19 July 2022.
Term of agreement: No fixed term. Made redundant in March 2023.
Details: Base annual salary in July 2022 of \$250,255 plus superannuation. 2 weeks' termination notice by either party, was eligible to be part of the consolidated entity's ESOP.

Medlab Clinical Limited
Directors' report
30 June 2023

Name: Luis Vitetta
Title: Director of Medical Research
Agreement commenced: 24 March 2013
Term of agreement: No fixed term. Resigned in July 2022.
Details: Base annual salary of \$297,250 plus superannuation. 2 weeks termination notice by either party, was eligible to be part of the consolidated entity's ESOP.

Name: David Rutolo
Title: Director of Science
Agreement commenced: 22 January 2015
Term of agreement: No fixed term. Made redundant on 30 June 2023.
Details: Base salary for the year ended 30 June 2023 of US\$120,000 plus employment benefits. 30 days termination notice by either party.

Name: Ian Curtin Smith
Title: Chief Information Officer
Agreement commenced: 9 July 2019
Term of agreement: No fixed term. Made redundant in March 2023.
Details: Base annual salary of \$205,000 plus superannuation. 4 weeks termination notice by either party, was eligible to be part of the consolidated entity's ESOP.

Key management personnel have no entitlement to termination payments in the event of removal for misconduct.

Share-based compensation

Issue of shares

There were no shares issued to directors and other key management personnel as part of compensation during the year ended 30 June 2023.

Options

The grant of options is designed to incentivise key management personnel by participating in the future growth and prosperity of the Company through share ownership and in recognition made to the Company by the key management personnel and their ongoing responsibility.

The terms and conditions of each grant of options over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or future reporting years are as follows:

Name	Number of options granted	Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
Michael Hall	2,000,000	12/11/2020	31/01/2021	31/10/2022	\$0.20	\$0.0460
Drew Townsend	2,000,000	12/11/2020	31/01/2021	31/10/2022	\$0.20	\$0.0460
Sean Hall	4,000,000	12/11/2020	31/01/2021	31/10/2022	\$0.20	\$0.0460
Laurence McAllister	4,000,000	12/11/2020	31/01/2021	31/10/2022	\$0.18	\$0.0530
Kerem Kaya	250,000	25/06/2021	25/06/2021	24/06/2024	\$0.21	\$0.0450
Cheryl Maley	1,500,000	18/10/2021	18/10/2021	18/10/2024	\$0.21	\$0.0516

Options granted carry no dividend or voting rights.

The number of options over ordinary shares granted to and vested by directors and other key management personnel as part of compensation during the year ended 30 June 2023 are set out below:

Name	Number of options granted during the year 2023	Number of options granted during the year 2022	Number of options vested during the year 2023	Number of options vested during the year 2022
Cheryl Maley	-	1,500,000	-	1,500,000

Medlab Clinical Limited
Directors' report
30 June 2023

The options granted to Michael Hall, Drew Townsend, Sean Hall and Laurence McAllister lapsed during the year ended 30 June 2023. There were no options exercised.

Additional information

The earnings of the Consolidated Entity for the five years to 30 June 2023 are summarised below:

	2023 \$	2022 \$	2021 \$	2020 \$	2019 \$
Revenue from ordinary activities	892,081	3,803,741	4,399,412	2,848,395	5,363,681
Loss after income tax	(6,433,297)	(7,228,814)	(12,402,829)	(13,488,317)	(8,174,096)

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	2023	2022	2021	2020	2019
Share price at financial year end (cents)*	-	5	15	15	35
Basic earnings per share (cents per share)**	(297)	(314)	(627)	(891)	(635)

* On 27 February 2023, the ASX suspended trading of the Company's shares.

** Basic earnings per share has been adjusted for the share consolidation that completed on 5 August 2022.

Additional disclosures relating to key management personnel

Shareholding

The number of shares in the Company held during the financial year by each director and other members of key management personnel of the Consolidated Entity, including their personally related parties, is set out below:

	Balance at the start of the year	Additions	Share consolidation*	Disposals/ other**	Balance at the end of the year
Ordinary shares					
Michael Hall	15,907,383	-	(15,801,334)	(106,049)	-
Drew Townsend	16,135,553	-	(16,027,983)	(107,570)	-
Sean Hall	58,731,189	124,821	(58,463,637)	-	392,373
Luis Vitetta	111,101	-	(110,360)	(741)	-
David Rutolo	3,000,000	-	(2,980,000)	(20,000)	-
Ian Curtin Smith	464,356	-	(461,260)	(3,096)	-
	<u>94,349,582</u>	<u>124,821</u>	<u>(93,844,574)</u>	<u>(237,456)</u>	<u>392,373</u>

* On 5 August 2022, the Company's shares were consolidated on a 150 to 1 basis.

** Includes the removal from the table of the share holdings for key management personnel who have resigned during the period.

Option holding

The number of options over ordinary shares in the Company held during the financial year by each director and other members of key management personnel of the Consolidated Entity, including their personally related parties, is set out below:

	Balance at the start of the year	Share consolidation*	Exercised	Expired/ forfeited/ other**	Balance at the end of the year
Options over ordinary shares					
Michael Hall	2,000,000	(1,986,667)	-	(13,333)	-
Drew Townsend	2,000,000	(1,986,667)	-	(13,333)	-
Sean Hall	4,000,000	(3,973,333)	-	(26,667)	-
Laurence McAllister	4,000,000	(3,973,333)	-	(26,667)	-
Cheryl Maley	1,500,000	(1,490,000)	-	(10,000)	-
Kerem Kaya	250,000	(248,333)	-	-	1,667
	<u>13,750,000</u>	<u>(13,658,333)</u>	<u>-</u>	<u>(90,000)</u>	<u>1,667</u>

Medlab Clinical Limited
Directors' report
30 June 2023

- * On 5 August 2022, the Company's shares were consolidated on a 150 to1 basis resulting in the consolidation of the outstanding options.
- ** With the exception of the options held by Cheryl Maley, all other options expired during the year. Cheryl Maley's options expire on 18 October 2024 and the movement represents the removal of Cheryl Maley from the table following her resignation as a Director on 26 February 2023.

This concludes the remuneration report, which has been audited.

Shares under option

Unissued ordinary shares of Medlab Clinical Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under option
29 June 2021	24 June 2024	\$0.21	7,222
18 October 2021	18 October 2024	\$0.21	10,000
			<u>17,222</u>

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate.

Shares issued on the exercise of options

There were no ordinary shares of Medlab Clinical Limited issued on the exercise of options during the year ended 30 June 2023 and up to the date of this report.

Indemnity and insurance of officers

The Company has indemnified the directors and executives of the Company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium in respect of a contract to insure the directors and executives of the Company against a liability to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Indemnity and insurance of auditor

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

Non-audit services

There were no non-audit services provided during the financial year by the auditor.

Officers of the Company who are former partners of MNSA Pty Limited

There are no officers of the Company who are former partners of MNSA Pty Limited.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out immediately after this directors' report.

Auditor

MNSA Pty Limited continues in office in accordance with section 327 of the *Corporations Act 2001*.

Medlab Clinical Limited
Directors' report
30 June 2023

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the *Corporations Act 2001*.

On behalf of the directors

A handwritten signature in black ink, appearing to read 'M Hudson', is written over a horizontal line.

M Hudson
Director

23 April 2024
Sydney



**AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF
THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF MEDLAB CLINICAL LIMITED AND CONTROLLED ENTITIES
ABN 51 169 149 071**

As the auditor for the audit of the financial report of Medlab Clinical Limited for the year ended 30 June 2023, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- i. the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- ii. any applicable code of professional conduct in relation to the audit.

MNSA PTY LTD

MNSA Pty Ltd

Mark Schiliro

Director

Sydney

Dated this 23rd of April 2024



Medlab Clinical Limited

Contents

30 June 2023

Consolidated statement of profit or loss and other comprehensive income	19
Consolidated statement of financial position	21
Consolidated statement of changes in equity	22
Consolidated statement of cash flows	23
Notes to the consolidated financial statements	24
Directors' declaration	53
Independent auditor's report to the members of Medlab Clinical Limited	54
Shareholder information	59
Corporate directory	60

General information

The financial statements cover Medlab Clinical Limited as a Consolidated Entity consisting of Medlab Clinical Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Medlab Clinical Limited's functional and presentation currency.

Medlab Clinical Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Nova Legal Corporate Lawyers
Level 2
50 Kings Park Road
West Perth WA 6005

A description of the nature of the Consolidated Entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 23 April 2024. The directors have the power to amend and reissue the financial statements.

Medlab Clinical Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2023

	Note	Consolidated 2023 \$	2022 \$
Revenue from continuing operations	4	892,081	1,282,434
Other income	5	3,462,408	4,704,110
Interest revenue		51,587	44,727
Expenses			
Raw materials and consumables used		(90,111)	(336,292)
Employee benefits expense		(4,154,262)	(7,104,763)
Depreciation and amortisation expense		(711,280)	(851,310)
Loss on disposal of assets		(31,234)	-
Make good provision reversed	19	266,796	-
Operating leases		(553,298)	(207,175)
Professional and consulting fees		(2,305,539)	(1,858,227)
R&D/trial expenses		(1,225,193)	(1,503,443)
Selling and marketing		(91,531)	(186,778)
Other expenses		(1,910,509)	(2,269,819)
Finance costs	6	(33,212)	(101,916)
Loss before income tax expense from continuing operations		(6,433,297)	(8,388,452)
Income tax expense	7	-	-
Loss after income tax expense from continuing operations		(6,433,297)	(8,388,452)
Profit after income tax expense from discontinued operations	8	-	1,159,638
Loss after income tax expense for the year		(6,433,297)	(7,228,814)
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		-	(5,269)
Foreign currency translation gain reclassified to profit or loss		(35,792)	-
Other comprehensive income for the year, net of tax		(35,792)	(5,269)
Total comprehensive income for the year		<u>(6,469,089)</u>	<u>(7,234,083)</u>
Loss for the year is attributable to:			
Non-controlling interest		345,070	(66,381)
Owners of Medlab Clinical Limited	22	(6,778,367)	(7,162,433)
		<u>(6,433,297)</u>	<u>(7,228,814)</u>
Total comprehensive income for the year is attributable to:			
Continuing operations		411,118	(93,370)
Discontinued operations		-	-
Non-controlling interest		<u>411,118</u>	<u>(93,370)</u>
Continuing operations		(6,880,207)	(8,300,351)
Discontinued operations		-	1,159,638
Owners of Medlab Clinical Limited		<u>(6,880,207)</u>	<u>(7,140,713)</u>
		<u>(6,469,089)</u>	<u>(7,234,083)</u>

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Medlab Clinical Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2023

		Consolidated 2023	2022
		Cents	Cents
Earnings per share for loss from continuing operations attributable to the owners of Medlab Clinical Limited			
Basic earnings per share	33	(297)	(365)
Diluted earnings per share	33	(297)	(365)
Earnings per share for profit from discontinued operations attributable to the owners of Medlab Clinical Limited			
Basic earnings per share	33	-	51
Diluted earnings per share	33	-	51
Earnings per share for loss attributable to the owners of Medlab Clinical Limited			
Basic earnings per share	33	(297)	(314)
Diluted earnings per share	33	(297)	(314)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Medlab Clinical Limited
Consolidated statement of financial position
As at 30 June 2023

	Note	Consolidated 2023 \$	2022 \$
Assets			
Current assets			
Cash and cash equivalents	9	225,991	5,191,031
Trade and other receivables	10	2,868,187	3,868,593
Inventories	11	-	80,107
Other	12	-	102,268
Total current assets		<u>3,094,178</u>	<u>9,241,999</u>
Non-current assets			
Trade and other receivables	10	-	226,267
Property, plant and equipment	13	-	344,306
Right-of-use assets	14	-	1,071,090
Other	12	50,000	482,941
Total non-current assets		<u>50,000</u>	<u>2,124,604</u>
Total assets		<u>3,144,178</u>	<u>11,366,603</u>
Liabilities			
Current liabilities			
Trade and other payables	15	1,614,469	1,461,954
Lease liabilities	17	-	568,233
Employee benefits	18	236,113	541,081
Provisions	19	-	305,422
Total current liabilities		<u>1,850,582</u>	<u>2,876,690</u>
Non-current liabilities			
Lease liabilities	17	-	554,560
Employee benefits	18	13,548	186,216
Total non-current liabilities		<u>13,548</u>	<u>740,776</u>
Total liabilities		<u>1,864,130</u>	<u>3,617,466</u>
Net assets		<u>1,280,048</u>	<u>7,749,137</u>
Equity			
Issued capital	20	66,811,113	66,811,113
Reserves	21	116,303	799,043
Accumulated losses	22	(65,647,659)	(59,529,093)
Equity attributable to the owners of Medlab Clinical Limited		<u>1,279,757</u>	<u>8,081,063</u>
Non-controlling interest		291	(331,926)
Total equity		<u>1,280,048</u>	<u>7,749,137</u>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Medlab Clinical Limited
Consolidated statement of changes in equity
For the year ended 30 June 2023

Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Non-controlling interest \$	Total equity \$
Balance at 1 July 2021	66,811,113	699,956	(52,366,660)	(238,556)	14,905,853
Loss after income tax expense for the year	-	-	(7,162,433)	(66,381)	(7,228,814)
Other comprehensive income for the year, net of tax	-	21,720	-	(26,989)	(5,269)
Total comprehensive income for the year	-	21,720	(7,162,433)	(93,370)	(7,234,083)
<i>Transactions with owners in their capacity as owners:</i>					
Share-based payments (note 21)	-	77,367	-	-	77,367
Balance at 30 June 2022	<u>66,811,113</u>	<u>799,043</u>	<u>(59,529,093)</u>	<u>(331,926)</u>	<u>7,749,137</u>
Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Non-controlling interest \$	Total equity \$
Balance at 1 July 2022	66,811,113	799,043	(59,529,093)	(331,926)	7,749,137
Profit/(loss) after income tax expense for the year	-	-	(6,778,367)	345,070	(6,433,297)
Other comprehensive income for the year, net of tax	-	(101,840)	-	66,048	(35,792)
Total comprehensive income for the year	-	(101,840)	(6,778,367)	411,118	(6,469,089)
<i>Transactions with owners in their capacity as owners:</i>					
Adjustment to non-controlling interests	-	-	78,901	(78,901)	-
Transfer from share-based payments reserve to accumulated losses (note 21)	-	(580,900)	580,900	-	-
Balance at 30 June 2023	<u>66,811,113</u>	<u>116,303</u>	<u>(65,647,659)</u>	<u>291</u>	<u>1,280,048</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Medlab Clinical Limited
Consolidated statement of cash flows
For the year ended 30 June 2023

	Note	Consolidated 2023 \$	2022 \$
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		1,490,990	5,704,078
Payments to suppliers and employees (inclusive of GST)		(10,671,238)	(18,265,329)
Interest received		51,587	44,727
Receipts from R&D Tax incentive and government grants		3,691,858	3,375,726
Interest and other finance costs paid		(33,212)	(126,735)
Net cash used in operating activities	32	(5,470,015)	(9,267,533)
Cash flows from investing activities			
Payments for property, plant and equipment	13	(16,217)	(28,609)
Payments for security deposits		-	(405)
Proceeds from disposal of investments		-	1,775,910
Proceeds from disposal of investments - deferred consideration	10	470,635	-
Proceeds from disposal of property, plant and equipment		95,406	-
Proceeds from release of security deposits		432,941	-
Net cash from investing activities		982,765	1,746,896
Cash flows from financing activities			
Repayment of principal portion of lease liabilities	32	(481,549)	(656,944)
Repayment of borrowings	32	-	(67,834)
Net cash used in financing activities		(481,549)	(724,778)
Net decrease in cash and cash equivalents		(4,968,799)	(8,245,415)
Cash and cash equivalents at the beginning of the financial year		5,191,031	13,434,762
Effects of exchange rate changes on cash and cash equivalents		3,759	1,684
Cash and cash equivalents at the end of the financial year	9	<u>225,991</u>	<u>5,191,031</u>

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out either in the respective notes or below. These policies have been consistently applied to all the years presented, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Consolidated Entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Going concern

For the year ended 30 June 2023, the consolidated entity incurred a loss of \$6,433,297 after income tax (2022: \$7,228,814 net loss) and net cash outflows from operating activities of \$5,470,015 (2022: \$9,267,533 net cash outflows).

On 27 February 2023, the ASX suspended trading of the Company's shares. Subsequently, Hall Chadwick was engaged as external consultants to assist the directors of the Company with an informal workout and restructure of the Company's financial affairs. The Company is currently operating in a care and maintenance capacity whilst the Directors devise and implement a corporate restructure plan. The Company has retrenched most of its workforce and is currently operating with skeleton staff for the purpose of the restructure. The restructuring process will involve dealing with current and new investors, as well as any interested parties to achieve the ongoing success and future of the Company which will ensure the best outcome for all stakeholders.

The ability of the consolidated entity to continue as a going concern is principally dependent upon the identification of a new business opportunity, execution of a binding agreement in respect of this new opportunity, and a capital raising sufficient to progress the new opportunity.

These conditions give rise to a material uncertainty, which may cast significant doubt over the consolidated entity's ability to continue as a going concern.

The Company is in discussions to obtain a strategic minerals business, with a focus on exposure to commodities, that are essential to the global net-zero agenda. The transaction is at an advanced stage in the negotiation process and the Company expects that the re-compliance process can begin subsequent to this. The expected raise of \$5M will be used to acquire the asset on a debt free/cash free basis and provide for working capital requirements across a 24-month period.- The Company has received indicative interest from investors and believes the capital raising process will be completed in a timely manner. Once the deal with this prospective company is agreed upon, the expected timeframe for quotation is 3-4 months, customary for these types of transactions (RTO).

The Directors have concluded that the going concern basis of preparation of the financial statements is appropriate and any uncertainty regarding going concern is mitigated by the following:

- The current net asset position of the company.
- The proposed new business opportunity.
- Subsequent proposed capital raising post completion of the transaction.

Based on the above, the Directors are of the opinion that at the date of signature of the financial report there are reasonable and supportable grounds to believe that the consolidated entity will be able to meet its liabilities from its assets in the ordinary course of business, for a period of not less than 12 months from the date of this financial report and has accordingly prepared the financial report on a going concern basis.

Should the consolidated entity be unable to continue as a going concern, it may be required to realise its assets and liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or to the amount and classification of liabilities that might be required should the consolidated entity not be able to continue as a going concern.

Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Note 1. Significant accounting policies (continued)

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Consolidated Entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

Parent entity information

In accordance with the *Corporations Act 2001*, these financial statements present the results of the Consolidated Entity only. Supplementary information about the parent entity is disclosed in note 29.

Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Medlab Clinical Limited ('Company' or 'parent entity') as at 30 June 2023 and the results of all subsidiaries for the year then ended. Medlab Clinical Limited and its subsidiaries together are referred to in these financial statements as the 'Consolidated Entity'.

Subsidiaries are all those entities over which the Consolidated Entity has control. The Consolidated Entity controls an entity when the Consolidated Entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Consolidated Entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the Consolidated Entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Consolidated Entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Non-controlling interest in the results and equity of subsidiaries are shown separately in the statement of profit or loss and other comprehensive income, statement of financial position and statement of changes in equity of the Consolidated Entity. Losses incurred by the Consolidated Entity are attributed to the non-controlling interest in full, even if that results in a deficit balance.

Where the Consolidated Entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The Consolidated Entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

Foreign currency translation

The financial statements are presented in Australian dollars, which is Medlab Clinical Limited's functional and presentation currency.

Foreign currency transactions

Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

Foreign operations

The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity.

Note 1. Significant accounting policies (continued)

The foreign currency reserve is recognised in profit or loss when the foreign operation or net investment is disposed of.

Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Consolidated Entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Consolidated Entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

Investments and other financial assets

Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. Such assets are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on both the business model within which such assets are held and the contractual cash flow characteristics of the financial asset unless an accounting mismatch is being avoided.

Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and the Consolidated Entity has transferred substantially all the risks and rewards of ownership. When there is no reasonable expectation of recovering part or all of a financial asset, its carrying value is written off.

Financial assets at amortised cost

A financial asset is measured at amortised cost only if both of the following conditions are met: (i) it is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (ii) the contractual terms of the financial asset represent contractual cash flows that are solely payments of principal and interest.

Impairment of financial assets

The Consolidated Entity recognises a loss allowance for expected credit losses on financial assets which are either measured at amortised cost or fair value through other comprehensive income. The measurement of the loss allowance depends upon the Consolidated Entity's assessment at the end of each reporting period as to whether the financial instrument's credit risk has increased significantly since initial recognition, based on reasonable and supportable information that is available, without undue cost or effort to obtain.

Where there has not been a significant increase in exposure to credit risk since initial recognition, a 12-month expected credit loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a default event that is possible within the next 12 months. Where a financial asset has become credit impaired or where it is determined that credit risk has increased significantly, the loss allowance is based on the asset's lifetime expected credit losses. The amount of expected credit loss recognised is measured on the basis of the probability weighted present value of anticipated cash shortfalls over the life of the instrument discounted at the original effective interest rate.

For financial assets mandatorily measured at fair value through other comprehensive income, the loss allowance is recognised in other comprehensive income with a corresponding expense through profit or loss. In all other cases, the loss allowance reduces the asset's carrying value with a corresponding expense through profit or loss.

Expenses

Special Access Scheme (SAS)

Any inventory purchased to be supplied under the Government's SAS or other approved trials are expensed when incurred.

Research and development

Research and development costs are expensed in the period in which they are incurred.

Note 1. Significant accounting policies (continued)

Patents and trademarks

Costs associated with patents and trademarks are expensed in the period in which they are incurred.

Impairment of non-financial assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

New Accounting Standards and Interpretations not yet mandatory or early adopted

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the Consolidated Entity for the annual reporting period ended 30 June 2023. The Consolidated Entity has not yet assessed the impact of these new or amended Accounting Standards and Interpretations.

Note 2. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Allowance for expected credit losses

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates, the impact of the Coronavirus (COVID-19) pandemic and forward-looking information that is available.

R&D tax incentive

The R&D tax incentive is recognised when there is reasonable assurance that the incentive will be received and all attached conditions will be complied with. The receivable for R&D tax incentive is calculated based on actual R&D expenses incurred, and knowledge of historical tax receivable in the past for similar projects that have been approved.

Note 3. Operating segments

Following the discontinuation of the Nutraceuticals business in the 30 June 2022 financial year, the consolidated entity only had one segment for the 30 June 2023 financial year. Consequently, segment information has not been presented for the 30 June 2023 financial year.

Identification of reportable operating segments

The Consolidated Entity is organised into two operating segments based on pharmaceutical research and nutraceutical sales. These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

The CODM reviews EBITDA (earnings before interest, tax, depreciation and amortisation). The accounting policies adopted for internal reporting to the CODM are consistent with those adopted in the financial statements.

The information reported to the CODM is on a monthly basis.

The principal products and services of each of these operating segments are as follows:

Nutraceutical	The supply of Medlab's self-branded nutraceutical range, predominantly in Australia (now discontinued)
Pharmaceutical	Various research activities (depression and oncology) and the supply of cannabis-based medicines

Intersegment transactions

There are no intersegment transactions.

Intersegment receivables, payables and loans

Intersegment loans are initially recognised at the consideration received. Intersegment loans receivable and loans payable that earn or incur non-market interest are not adjusted to fair value based on market interest rates. Intersegment loans are eliminated on consolidation.

Major customers

During the year ended 30 June 2022, there was no customer who contributed more than 10% of the Consolidated Entity's external revenue.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 3. Operating segments (continued)

Operating segment information

	Nutraceutical \$	Pharmaceutical Research \$	Corporate/ Other \$	Total \$
Consolidated - 2022				
Revenue				
Sales to external customers	2,618,067	1,282,434	-	3,900,501
Provision for sales returns, promotional costs and other rebates	(96,760)	-	-	(96,760)
Total sales revenue	2,521,307	1,282,434	-	3,803,741
Interest revenue	-	-	44,727	44,727
Total revenue	<u>2,521,307</u>	<u>1,282,434</u>	<u>44,727</u>	<u>3,848,468</u>
EBITDA	<u>(48,214)</u>	<u>(7,467,917)</u>	<u>-</u>	<u>(7,516,131)</u>
Depreciation and amortisation				(851,310)
Loss on disposal of discontinued operation				1,195,816
Interest revenue				44,727
Finance costs				(101,916)
Loss before income tax expense				<u>(7,228,814)</u>
Income tax expense				-
Loss after income tax expense				<u>(7,228,814)</u>
Assets				
Segment assets	470,635	5,221,996	5,673,972	11,366,603
Total assets				<u>11,366,603</u>
<i>Total assets includes:</i>				
Acquisition of non-current assets	-	28,609	-	28,609
Liabilities				
Segment liabilities	-	3,617,466	-	3,617,466
Total liabilities				<u>3,617,466</u>

Geographical information

For the financial years ended 30 June 2023 and 30 June 2022, there was no revenue from external customers attributed to foreign countries.

Accounting policy for operating segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

Note 4. Revenue

	Consolidated	
	2023	2022
	\$	\$
From continuing operations		
Sale of goods (net discounts)	892,081	1,379,195
Sales returns	-	(96,761)
Revenue from continuing operations	<u>892,081</u>	<u>1,282,434</u>

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 4. Revenue (continued)

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

	Consolidated	
	2023	2022
	\$	\$
<i>Major product lines</i>		
Pharmaceuticals	<u>892,081</u>	<u>1,282,434</u>
<i>Timing of revenue recognition</i>		
Goods transferred at a point in time	<u>892,081</u>	<u>1,282,434</u>

Included in the following tables are reconciliations of the disaggregated revenue with the consolidated entity's reportable segments (refer note 3). The consolidated entity only had one reportable segment for the year ended 30 June 2023.

	Nutraceutical	Pharmaceutical	Total
	\$	\$	\$
30 June 2022			
<i>Continuing operations</i>			
Pharmaceutical	-	1,282,434	1,282,434
<i>Discontinuing operations</i>			
Nutraceutical	2,521,307	-	2,521,307
Total segment revenue	<u>2,521,307</u>	<u>1,282,434</u>	<u>3,803,741</u>

Accounting policy for revenue recognition

The Consolidated Entity recognises revenue as follows:

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the Consolidated Entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the Consolidated Entity: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

Sale of goods

Sale of goods revenue is recognised at the point of sale, which is at the time when the customer's orders are despatched. Amounts disclosed as revenue are net of sales returns and trade discounts.

Interest

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 4. Revenue (continued)

Other revenue

Other revenue is recognised when it is received or when the right to receive payment is established.

Note 5. Other income

	Consolidated	
	2023	2022
	\$	\$
Net foreign exchange gain	27,729	-
Government grants	36,600	61,954
Project termination credit	466,713	-
Net gain on lease termination	47,593	-
R&D tax incentive	2,873,294	4,621,501
Other	10,479	20,655
	<u>3,462,408</u>	<u>4,704,110</u>
Other income	<u>3,462,408</u>	<u>4,704,110</u>

Note 6. Expenses

	Consolidated	
	2023	2022
	\$	\$
Loss before income tax from continuing operations includes the following specific expenses:		
<i>Finance costs</i>		
Interest and finance charges paid/payable on borrowings	604	44,702
Interest and finance charges paid/payable on lease liabilities	32,608	57,214
	<u>33,212</u>	<u>101,916</u>
Finance costs expensed	<u>33,212</u>	<u>101,916</u>
<i>Superannuation expense</i>		
Defined contribution superannuation expense	343,694	565,328
	<u>343,694</u>	<u>565,328</u>
<i>Share-based payments expense</i>		
Share-based payments expense	-	77,367
	<u>-</u>	<u>77,367</u>

Other expenses includes the following specific expenses (continuing and discontinued operations):

	Consolidated	
	2023	2022
	\$	\$
Educational and compliance	71,943	115,215
Insurance	323,568	246,045
Lab consumables	947	17,050
Software licences	121,401	118,045
Telephone and internet	43,629	63,026
Travel	53,900	100,047

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 7. Income tax

	Consolidated 2023 \$	2022 \$
<i>Income tax expense</i>		
Current tax	-	-
Deferred tax - origination and reversal of temporary differences	-	-
Aggregate income tax expense	<u>-</u>	<u>-</u>
<i>Numerical reconciliation of income tax expense and tax at the statutory rate</i>		
Loss before income tax expense from continuing operations	(6,433,297)	(8,388,452)
Profit before income tax expense from discontinued operations	-	1,159,638
	<u>(6,433,297)</u>	<u>(7,228,814)</u>
Tax at the statutory tax rate of 25%	(1,608,324)	(1,807,204)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Non-deductible R&D expense	1,728,060	2,090,470
Non-deductible expenses	322,253	13,337
Non-assessable income	-	(750)
R&D tax incentive	<u>(718,323)</u>	<u>(1,155,375)</u>
	(276,334)	(859,522)
Difference in overseas tax rates	-	(35,404)
Current year tax losses and temporary differences not recognised	<u>276,334</u>	<u>894,926</u>
Income tax expense	<u>-</u>	<u>-</u>

The economic entity has separate tax entities within Australia, the UK and the United States. All tax jurisdictions have tax losses, which are not recognised in their books at 30 June 2023. The unused tax losses held in the Australian group companies as at 30 June 2023 are \$30,186,724, \$5,671,943 (USD) was held in the US companies and a further \$216,920 (GBP) was held in the UK company. The tax losses are available for offset against future taxable profits of the companies in which losses arose within each tax jurisdiction subject to certain conditions being met.

Accounting policy for income tax

The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:

- When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or
- When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 7. Income tax (continued)

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

Note 8. Discontinued operations

Description

On 19 October 2021, the Company licenced its Australian nutraceutical business to PharmaCare Pty Ltd for for a cash consideration of \$750,000 and \$1,025,910 for the inventory. The principal assets that were sold comprised registered patents and trademarks, inventory, customer lists, and material contracts.

In terms of the sale agreement, the Company is entitled to receive an earn-out of the greater of \$250,000 or 5% of net sales for each of the two successive years following completion. At the time of the sale, the fair value of the minimum additional cash consideration was determined to be \$445,816 and has been recognised as a deferred consideration receivable (refer note 10). Subsequent to recognition, the deferred consideration receivable is accounted for at amortised cost and at 30 June 2022, the receivable increased to \$470,635 as a result of the unwinding of the discount. The fair value of any contingent consideration above the minimum annual earn-out of \$250,000 has been assessed to have a nil fair value.

Financial performance information

	Consolidated	
	2023	2022
	\$	\$
Sales of goods (net discounts)	-	2,775,239
Promotional costs and other rebates	-	(253,932)
Total revenue	-	2,521,307
Other income - Provision for expected credit losses on receivables - unused provision	-	400,000
Raw materials and consumables used	-	(2,027,305)
Employee benefits expense	-	(724,969)
Selling and marketing	-	(152,366)
Other expenses	-	(52,845)
Total expenses	-	(2,957,485)
Loss before income tax expense	-	(36,178)
Income tax expense	-	-
Loss after income tax expense	-	(36,178)
Gain on disposal before income tax	-	1,195,816
Income tax expense	-	-
Gain on disposal after income tax expense	-	1,195,816
Profit after income tax expense from discontinued operations	-	1,159,638

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 8. Discontinued operations (continued)

Cash flow information

	Consolidated	
	2023	2022
	\$	\$
Net cash used in operating activities	-	(1,483,239)
Net cash from investing activities	-	-
Net cash from financing activities	-	-
	<hr/>	<hr/>
Net decrease in cash and cash equivalents from discontinued operations	<hr/> - <hr/>	<hr/> (1,483,239) <hr/>

Carrying amounts of assets and liabilities disposed

	Consolidated	
	2023	2022
	\$	\$
Inventories	-	1,025,910
Total assets	<hr/> -	<hr/> 1,025,910
	<hr/>	<hr/>
Net assets	<hr/> - <hr/>	<hr/> 1,025,910 <hr/>

Details of the disposal

	Consolidated	
	2023	2022
	\$	\$
Total sale consideration	-	2,221,726
Carrying amount of net assets disposed	<hr/> -	<hr/> (1,025,910)
	<hr/>	<hr/>
Gain on disposal before income tax	<hr/> -	<hr/> 1,195,816
	<hr/>	<hr/>
Gain on disposal after income tax	<hr/> - <hr/>	<hr/> 1,195,816 <hr/>

Accounting policy for discontinued operations

A discontinued operation is a component of the Consolidated Entity that has been disposed of or is classified as held for sale and that represents a separate major line of business or geographical area of operations, is part of a single co-ordinated plan to dispose of such a line of business or area of operations, or is a subsidiary acquired exclusively with a view to resale. The results of discontinued operations are presented separately on the face of the statement of profit or loss and other comprehensive income.

Note 9. Cash and cash equivalents

	Consolidated	
	2023	2022
	\$	\$
<i>Current assets</i>		
Cash at bank	<hr/> 225,991 <hr/>	<hr/> 5,191,031 <hr/>

Accounting policy for cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 10. Trade and other receivables

	Consolidated	
	2023	2022
	\$	\$
<i>Current assets</i>		
Trade receivables	103,399	88,982
Less: Allowance for expected credit losses	-	(10,000)
	<u>103,399</u>	<u>78,982</u>
Other receivables	29,607	95,243
Research and development tax incentive	2,735,181	3,450,000
Deferred consideration	-	244,368
	<u>2,868,187</u>	<u>3,868,593</u>
<i>Non-current assets</i>		
Deferred consideration	-	226,267
	<u>2,868,187</u>	<u>4,094,860</u>

Deferred consideration

On 19 October 2021, the Company licenced its Australian nutraceutical business to PharmaCare Pty Ltd (refer note 8). The Company was entitled to receive an earn-out of the greater of \$250,000 or 5% of net sales for each of the two successive years following completion. The deferred consideration represented the fair value of the minimum earn-out the company would receive.

Allowance for expected credit losses

The ageing of the past due but not impaired receivables are as follows:

	Consolidated	
	2023	2022
	\$	\$
0 to 3 months overdue	<u>103,399</u>	<u>2,973</u>

The ageing of the impaired receivables provided for above are as follows:

	Consolidated	
	2023	2022
	\$	\$
0 to 3 months overdue	<u>-</u>	<u>10,000</u>

Movements in the allowance for expected credit losses are as follows:

	Consolidated	
	2023	2022
	\$	\$
Opening balance	10,000	675,000
Additional provisions recognised	-	10,000
Provision utilised/reversed	<u>(10,000)</u>	<u>(675,000)</u>
Closing balance	<u>-</u>	<u>10,000</u>

Accounting policy for trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 10. Trade and other receivables (continued)

The Consolidated Entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Note 11. Inventories

	Consolidated	
	2023	2022
	\$	\$
<i>Current assets</i>		
Raw materials - at cost	-	56,774
Finished goods - at cost	-	23,333
	-	80,107

Accounting policy for inventories

Raw materials, work in progress and finished goods are stated at the lower of cost and net realisable value on a 'first in first out' basis. Cost comprises of direct materials and delivery costs, direct labour, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Any inventory purchased to be supplied under the Government's SAS or other approved trials were expensed when incurred.

Note 12. Other

	Consolidated	
	2023	2022
	\$	\$
<i>Current assets</i>		
Prepayments	-	99,268
Other current assets	-	3,000
	-	102,268
<i>Non-current assets</i>		
Security bonds and guarantees	50,000	482,941
	50,000	585,209

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 13. Property, plant and equipment

	Consolidated	
	2023	2022
	\$	\$
<i>Non-current assets</i>		
Leasehold improvements - at cost	-	429,102
Less: Accumulated depreciation	-	(303,786)
	-	125,316
Plant and equipment - at cost	-	611,227
Less: Accumulated depreciation	-	(471,038)
	-	140,189
Office furniture and equipment	-	480,377
Less: Accumulated depreciation	-	(401,576)
	-	78,801
	-	344,306

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Leasehold improvements \$	Plant and equipment \$	Office furniture and equipment \$	Total \$
Balance at 1 July 2021	170,637	191,161	121,518	483,316
Additions	-	3,672	24,937	28,609
Exchange differences	-	-	948	948
Depreciation expense	(45,321)	(54,644)	(68,602)	(168,567)
Balance at 30 June 2022	125,316	140,189	78,801	344,306
Additions	16,217	-	-	16,217
Disposals	(39,542)	(51,071)	(36,027)	(126,640)
Exchange differences	-	-	(42)	(42)
Depreciation expense	(101,991)	(89,118)	(42,732)	(233,841)
Balance at 30 June 2023	-	-	-	-

Accounting policy for property, plant and equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment over their expected useful lives as follows:

Leasehold improvements	3-15 years
Plant and equipment	3-13 years
Office furniture and equipment	3-10 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

Leasehold improvements are depreciated over the unexpired period of the lease or the estimated useful life of the assets, whichever is shorter.

Note 13. Property, plant and equipment (continued)

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Consolidated Entity. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.

Note 14. Right-of-use assets

	Consolidated	
	2023	2022
	\$	\$
<i>Non-current assets</i>		
Leasehold properties - right-of-use	-	2,726,212
Less: Accumulated depreciation	-	(1,655,122)
	<u>-</u>	<u>1,071,090</u>

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Leasehold properties \$
Balance at 1 July 2021	1,600,978
Additions	152,495
Exchange differences	360
Depreciation expense	(682,743)
Balance at 30 June 2022	1,071,090
Exchange differences	-
Lease termination	(593,651)
Depreciation expense	(477,439)
Balance at 30 June 2023	<u>-</u>

Accounting policy for right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Consolidated Entity expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Consolidated Entity has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

Note 15. Trade and other payables

	Consolidated	
	2023	2022
	\$	\$
<i>Current liabilities</i>		
Trade payables	1,217,390	530,958
Accrued expenses	86,731	546,015
Sundry payables	310,348	384,981
	<u>1,614,469</u>	<u>1,461,954</u>

Refer to note 24 for further information on financial instruments.

Accounting policy for trade and other payables

These amounts represent liabilities for goods and services provided to the Consolidated Entity prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Note 16. Borrowings

Insurance premium funding

At 30 June 2021, the consolidated entity had an insurance premium funding facility established with Hunter Premium. The facility was over a 12-month term with an interest rate of 8%.

Note 17. Lease liabilities

	Consolidated	
	2023	2022
	\$	\$
<i>Current liabilities</i>		
Lease liability	-	568,233
<i>Non-current liabilities</i>		
Lease liability	-	554,560
	<u>-</u>	<u>1,122,793</u>

Refer to note 24 for further information on financial instruments.

Accounting policy for lease liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Consolidated Entity's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 18. Employee benefits

	Consolidated	
	2023	2022
	\$	\$
<i>Current liabilities</i>		
Annual leave	157,102	463,120
Long service leave	79,011	77,961
	<u>236,113</u>	<u>541,081</u>
<i>Non-current liabilities</i>		
Long service leave	13,548	186,216
	<u>249,661</u>	<u>727,297</u>

Accounting policy for employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Defined contribution superannuation expense

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

Note 19. Provisions

	Consolidated	
	2023	2022
	\$	\$
<i>Current liabilities</i>		
Lease make good	<u>-</u>	<u>305,422</u>
<i>Movements in lease make good</i>		
		Lease make-good
		\$
Consolidated - 2023		
Carrying amount at the start of the year		305,422
Amounts used		(38,626)
Unused amounts reversed		<u>(266,796)</u>
Carrying amount at the end of the year		<u>-</u>

Note 19. Provisions (continued)

Accounting policy for provisions

Provisions are recognised when the Consolidated Entity has a present (legal or constructive) obligation as a result of a past event, it is probable the Consolidated Entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost.

Note 20. Issued capital

	2023	Consolidated		
	Shares	2022	2023	2022
		Shares	\$	\$
Ordinary shares - fully paid	<u>2,283,502</u>	<u>342,175,671</u>	<u>66,811,113</u>	<u>66,811,113</u>

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2021	<u>342,175,671</u>		<u>66,811,113</u>
Balance	30 June 2022	342,175,671		66,811,113
Share consolidation (150:1 basis)	5 August 2022	<u>(339,892,169)</u>		<u>-</u>
Balance	30 June 2023	<u>2,283,502</u>		<u>66,811,113</u>

Accounting policy for issued capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Capital risk management

The Consolidated Entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the Consolidated Entity may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 20. Issued capital (continued)

The Consolidated Entity would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company's share price at the time of the investment. The Consolidated Entity would also look to raise capital if there is a need for additional funds for working capital requirements.

The Consolidated Entity does not have any externally imposed capital requirements.

The capital risk management policy remains unchanged from the 2022 Annual Report.

The Consolidated Entity monitors capital on the basis of its working capital position (i.e. liquidity risk). The Consolidated Entity's net working capital at 30 June 2023 was \$1,243,596 (2022: \$6,365,309). Refer to note 1 - Going concern.

Note 21. Reserves

	Consolidated	
	2023	2022
	\$	\$
Foreign currency reserve	-	101,840
Share-based payments reserve	116,303	697,203
	<u>116,303</u>	<u>799,043</u>

Foreign currency reserve

The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.

Share-based payments reserve

The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration, and other parties as part of their compensation for services.

Movements in reserves

Movements in each class of reserve during the current and previous financial year are set out below:

Consolidated	Share-based payments reserve \$	Foreign currency reserve \$	Total \$
Balance at 1 July 2021	619,836	80,120	699,956
Foreign currency translation	-	21,720	21,720
Share-based payment expenses	77,367	-	77,367
	<u>697,203</u>	<u>101,840</u>	<u>799,043</u>
Balance at 30 June 2022	697,203	101,840	799,043
Transfer to profit or loss	-	(101,840)	(101,840)
Transfer to accumulated losses	(580,900)	-	(580,900)
	<u>116,303</u>	<u>-</u>	<u>116,303</u>
Balance at 30 June 2023	<u>116,303</u>	<u>-</u>	<u>116,303</u>

Note 22. Accumulated losses

	Consolidated	
	2023	2022
	\$	\$
Accumulated losses at the beginning of the financial year	(59,529,093)	(52,366,660)
Loss after income tax expense for the year	(6,778,367)	(7,162,433)
Transfer from share-based payments reserve	580,900	-
Transfer from non-controlling interests	78,901	-
	<u>78,901</u>	<u>-</u>
Accumulated losses at the end of the financial year	<u>(65,647,659)</u>	<u>(59,529,093)</u>

Note 23. Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Note 24. Financial instruments

Financial risk management objectives

The Consolidated Entity's activities expose it to a variety of financial risks: market risk (including foreign currency risk), credit risk and liquidity risk. The Consolidated Entity's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Consolidated Entity. The Consolidated Entity uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of foreign exchange and other price risks, ageing analysis for credit risk.

Risk management is carried out by the CFO ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the Consolidated Entity and appropriate procedures, controls and risk limits. Finance identifies, evaluates and hedges financial risks within the Consolidated Entity's operating units. Finance reports to the Board on a monthly basis.

Market risk

Foreign currency risk

The Consolidated Entity undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.

Foreign exchange risk arises from future commercial transactions, net assets of subsidiaries and recognised financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

The carrying amount of the Consolidated Entity's foreign currency denominated financial assets and financial liabilities at the reporting date were as follows:

	Assets		Liabilities	
	2023	2022	2023	2022
Consolidated	\$	\$	\$	\$
US dollars	-	146,995	766,428	140,700
Pound Sterling	-	8,799	2,005	9,902
	<u>-</u>	<u>155,794</u>	<u>768,433</u>	<u>150,602</u>

Note 24. Financial instruments (continued)

The Consolidated Entity had net liabilities denominated in foreign currencies of \$768,433 (assets of \$nil less liabilities of \$768,433) as at 30 June 2023 (2022: net assets of \$5,192 (assets of \$155,794 less liabilities of \$150,602)). Based on this exposure, had the Australian dollar weakened by 10%/strengthened by 5% (2022: weakened by 10%/strengthened by 5%) against these foreign currencies with all other variables held constant, the Consolidated Entity's loss before tax for the year would have been \$85,381 higher/\$36,592 lower (2022: \$94,948 lower/\$54,970 higher). The percentage change is the expected overall volatility of the significant currencies, which is based on management's assessment of reasonable possible fluctuations taking into consideration movements over the last 6 months each year and the spot rate at each reporting date. The actual foreign exchange gain for the year ended 30 June 2023 was \$567,761 (2022: loss of \$51,129).

Price risk

The Consolidated Entity is not exposed to any significant price risk.

Interest rate risk

The Consolidated Entity is not exposed to any significant interest rate risk.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Consolidated Entity. The Consolidated Entity has a strict code of credit, including obtaining agency credit information, confirming references and setting appropriate credit limits. The Consolidated Entity obtains guarantees where appropriate to mitigate credit risk. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements. The Consolidated Entity does not hold any collateral.

The Consolidated Entity has adopted a lifetime expected loss allowance in estimating expected credit losses to trade receivables through the use of a provisions matrix using fixed rates of credit loss provisioning. These provisions are considered representative across all customers of the Consolidated Entity based on recent sales experience, historical collection rates and forward-looking information that is available.

Included in trade receivables at 30 June 2023 is a balance of \$83,930 representing 81% of the total trade receivables. Management is confident that this balance is recoverable. The Consolidated Entity had no significant credit risk exposure at 30 June 2022.

Liquidity risk

Vigilant liquidity risk management requires the Consolidated Entity to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The Consolidated Entity manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Remaining contractual maturities

The following tables detail the Consolidated Entity's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

	1 year or less \$	Between 1 and 2 years \$	Between 2 and 5 years \$	Over 5 years \$	Remaining contractual maturities \$
Consolidated - 2023					
Non-derivatives					
<i>Non-interest bearing</i>					
Trade and other payables	1,614,469	-	-	-	1,614,469
Total non-derivatives	1,614,469	-	-	-	1,614,469

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 24. Financial instruments (continued)

	1 year or less \$	Between 1 and 2 years \$	Between 2 and 5 years \$	Over 5 years \$	Remaining contractual maturities \$
Consolidated - 2022					
Non-derivatives					
<i>Non-interest bearing</i>					
Trade and other payables	1,461,954	-	-	-	1,461,954
<i>Interest-bearing - fixed rate</i>					
Lease liability	600,370	535,740	27,965	-	1,164,075
Total non-derivatives	<u>2,062,324</u>	<u>535,740</u>	<u>27,965</u>	<u>-</u>	<u>2,626,029</u>

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

Note 25. Key management personnel disclosures

Compensation

The aggregate compensation made to directors and other members of key management personnel of the Consolidated Entity is set out below:

	Consolidated	
	2023	2022
	\$	\$
Short-term employee benefits	1,570,617	2,382,579
Post-employment benefits	129,232	151,524
Long-term benefits	7,079	34,534
Termination benefits	66,097	-
Share-based payments	-	179,805
	<u>1,773,025</u>	<u>2,748,442</u>

Note 26. Remuneration of auditors

MNSA Pty Limited were appointed auditors of the Company for the financial year ended 30 June 2023. ESV Business Advice and Accounting, the the Company's former auditors, carried out a review of the Company's 31 December 2022 half-year financial report.

	Consolidated	
	2023	2022
	\$	\$
<i>Audit services</i>		
MNSA Pty Limited - Audit of the financial statements	15,000	-
ESV Business Advice and Accounting - Audit or review of the financial statements	<u>23,805</u>	<u>68,400</u>
	<u>38,805</u>	<u>68,400</u>
<i>Other services</i>		
ESV Business Advice and Accounting - Assisting overseas advisers review audit files	-	4,900
	<u>38,805</u>	<u>73,300</u>

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 27. Contingent liabilities

The Company had given bank guarantees as at 30 June 2023 of \$50,000 towards the corporate credit cards.

Note 28. Related party transactions

Parent entity

Medlab Clinical Limited is the parent entity.

Subsidiaries

Interests in subsidiaries are set out in note 30.

Key management personnel

Disclosures relating to key management personnel are set out in note 25 and the remuneration report included in the directors' report.

Transactions with related parties

The following transactions occurred with related parties:

	Consolidated	
	2023	2022
	\$	\$
Payment for goods and services:		
Payment for taxation services from Hall Chadwick - director-related entity of Drew Townsend	13,000	17,032
Payment for employee benefits - related party to Sean Hall	162,280	160,897

Receivable from and payable to related parties

There were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

Terms and conditions

All transactions were made on normal commercial terms and conditions and at market rates.

Note 29. Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	Parent	
	2023	2022
	\$	\$
Loss after income tax	<u>(7,959,766)</u>	<u>(44,923,653)</u>
Total comprehensive income	<u>(7,959,766)</u>	<u>(44,923,653)</u>

The loss after tax for the year ended 30 June 2022 includes an impairment of inter-group loans of \$38,447,501.

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 29. Parent entity information (continued)

Statement of financial position

	Parent	
	2023	2022
	\$	\$
Total current assets	2,959,505	8,717,917
Total assets	2,959,505	11,111,344
Total current liabilities	1,785,244	1,832,675
Total liabilities	1,798,792	1,990,865
Net assets	1,160,713	9,120,479
Equity		
Issued capital	66,811,113	66,811,113
Share-based payments reserve	116,303	697,203
Accumulated losses	(65,766,703)	(58,387,837)
Total equity	1,160,713	9,120,479

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries

The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2023 and 30 June 2022.

Contingent liabilities

Other than as disclosed in note 27, the parent entity had no contingent liabilities as at 30 June 2023 and 30 June 2022.

Capital commitments - Property, plant and equipment

The parent entity had no capital commitments for property, plant and equipment as at 30 June 2023 and 30 June 2022.

Significant accounting policies

The accounting policies of the parent entity are consistent with those of the Consolidated Entity, as disclosed in note 1, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Note 30. Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1:

Name	Principal place of business / Country of incorporation	Ownership interest	
		2023	2022
		%	%
Medlab Pty Ltd	Australia	100%	100%
Medlab Clinical US Inc*	United States of America	100%	100%
Medlab IP Pty Ltd*	Australia	100%	100%
Medlab Research Pty Ltd***	Australia	100%	100%
Medlab Nutraceuticals Inc***	United States of America	60%	60%
Medlab Research Ltd**	United Kingdom	100%	100%
MDC Europe Ltd***	Malta	100%	100%

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 30. Interests in subsidiaries (continued)

- * Medlab Clinical US Inc and Medlab IP Pty Ltd were sold to Dr. Sean Hall (Chairman) on 12 January 2024 (refer to note 31).
- ** Medlab Research Ltd was deregistered in January 2024.
- *** Medlab Research Pty Ltd, Medlab Nutraceuticals Inc and MDC Europe Ltd were deregistered during the half year ended 31 December 2023.

Note 31. Events after the reporting period

On 12 January 2024, the Company completed the sale of 100% of the issued share capital in Medlab IP Pty Ltd and Medlab Clinical US Inc., from its wholly owned subsidiary Medlab Pty Ltd to Dr. Sean Hall. In consideration for the disposal, Dr. Sean Hall (or his associated entity) agrees to pay the Entitled Shareholders, a 20% royalty for a period of 4 years commencing on the date of settlement of the sale agreement. The Entitled Shareholders are those shareholders of Medlab Limited as determined at the date of settlement.

No other matter or circumstance has arisen since 30 June 2023 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years.

Note 32. Cash flow information

Reconciliation of loss after income tax to net cash used in operating activities

	Consolidated	
	2023	2022
	\$	\$
Loss after income tax expense for the year	(6,433,297)	(7,228,814)
Adjustments for:		
Depreciation and amortisation	711,280	851,310
Share-based payments	-	77,367
Net loss/(gain) on disposal of non-current assets	31,234	(1,195,816)
Net gain on lease termination	(47,593)	-
Net foreign exchange gain transferred from reserves	(35,792)	-
Finance costs - non-cash	-	(24,819)
Foreign currency differences	(3,717)	(8,261)
Change in operating assets and liabilities:		
Decrease/(increase) in trade and other receivables	756,038	(268,300)
Decrease/(increase) in inventories	80,107	(313,646)
Decrease in prepayments	99,268	329,815
Decrease in other operating assets	3,000	64,335
Increase/(decrease) in trade and other payables	152,515	(1,528,851)
Decrease in employee benefits	(477,636)	(21,853)
Decrease in other provisions	(305,422)	-
Net cash used in operating activities	<u>(5,470,015)</u>	<u>(9,267,533)</u>

Medlab Clinical Limited
Notes to the consolidated financial statements
30 June 2023

Note 32. Cash flow information (continued)

Changes in liabilities arising from financing activities

Consolidated	Leases \$	Insurance premium funding \$	Total \$
Balance at 1 July 2021	1,627,242	67,834	1,695,076
Net cash used in financing activities	(656,944)	(67,834)	(724,778)
Acquisition of leases	152,495	-	152,495
Balance at 30 June 2022	1,122,793	-	1,122,793
Net cash used in financing activities	(481,549)	-	(481,549)
Lease termination	(641,244)	-	(641,244)
Balance at 30 June 2023	-	-	-

Note 33. Earnings per share

	Consolidated 2023 \$	Consolidated 2022 \$
<i>Earnings per share for loss from continuing operations</i>		
Loss after income tax	(6,433,297)	(8,388,452)
Non-controlling interest	(345,070)	66,381
Loss after income tax attributable to the owners of Medlab Clinical Limited	<u>(6,778,367)</u>	<u>(8,322,071)</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	2,283,502	2,281,171
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>2,283,502</u>	<u>2,281,171</u>
	Cents	Cents
Basic earnings per share	(297)	(365)
Diluted earnings per share	(297)	(365)
	Consolidated 2023 \$	Consolidated 2022 \$
<i>Earnings per share for profit from discontinued operations</i>		
Profit after income tax attributable to the owners of Medlab Clinical Limited	-	1,159,638
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	2,283,502	2,281,171
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>2,283,502</u>	<u>2,281,171</u>
	Cents	Cents
Basic earnings per share	-	51
Diluted earnings per share	-	51

Note 33. Earnings per share (continued)

	Consolidated 2023 \$	2022 \$
<i>Earnings per share for loss</i>		
Loss after income tax	(6,433,297)	(7,228,814)
Non-controlling interest	(345,070)	66,381
Loss after income tax attributable to the owners of Medlab Clinical Limited	<u>(6,778,367)</u>	<u>(7,162,433)</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>2,283,502</u>	<u>2,281,171</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>2,283,502</u>	<u>2,281,171</u>
	Cents	Cents
Basic earnings per share	(297)	(314)
Diluted earnings per share	(297)	(314)

Share consolidation after the reporting period and impact on weighted average number of shares

On 5 August 2022, the company completed a share consolidation at the ratio of 150 fully paid ordinary shares into 1 fully paid ordinary share (refer to note 20). The weighted average number of ordinary shares for 30 June 2022 has been adjusted for the effect of the share consolidation, in accordance with AASB 133 *Earnings per share*.

Accounting policy for earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the owners of Medlab Clinical Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

Note 34. Share-based payments

Employee share option plan

An employee share option plan has been established by the Consolidated Entity and approved by shareholders at a general meeting, whereby the Consolidated Entity may, at the discretion of the Board of Directors, grant options over ordinary shares in the Company to certain staff of the Consolidated Entity. The options are issued for nil consideration and are granted in accordance with performance guidelines established by the Nomination and Remuneration Committee. No options have been issued under this employee share option plan as of the date of this financial report.

On 12 November 2020, the Company granted 12,000,000 unlisted options to the following Directors for nil consideration:

- Michael Hall - 2,000,000 options exercisable at 20 cents per share
- Drew Townsend - 2,000,000 options exercisable at 20 cents per share
- Sean Hall - 4,000,000 options exercisable at 20 cents per share
- Laurence McAllister - 4,000,000 options exercisable at 18 cents per share

The grant of options was designed to incentivise the Directors by participating in the future growth and prosperity of the Consolidated Entity through share ownership and in recognition made to the Consolidated Entity by the Directors and their ongoing responsibility. The options vested on 31 January 2021 and expired, unexercised, on 31 October 2022. The value of the options at grant date was \$580,000.

Note 34. Share-based payments (continued)

On 25 June 2021, the Company granted 833,333 and 250,000 unlisted options to the Investor Relations Consultant and the Chief Financial Officer respectively. The options are exercisable at 21 cents per share. The options vest on grant date and expire on 24 June 2024. The value of the options at grant date was \$39,836.

On 18 October 2021, the company granted 1,500,000 options to Ms Cheryl Maley (Non-Executive Director) for nil consideration. The options vested on the grant date and expire on 16 October 2024. The fair value of the options at grant date was \$77,367. The purpose of the issue of the options was to provide an incentive to Ms Maley to continue to play a key and integral role in the future benefit of the company and therefore increase shareholder value. Ms Maley resigned as a Director on 26 February 2023.

Set out below are summaries of other options granted:

2023

Grant date	Expiry date	Exercise price	Balance at the start of the year	Share consolidation	Exercised	Expired/ forfeited/ other	Balance at the end of the year
12/11/2020	31/10/2022	\$0.20	8,000,000	(7,946,667)	-	(53,333)	-
12/11/2020	31/10/2022	\$0.18	4,000,000	(3,973,333)	-	(26,667)	-
25/06/2021	24/06/2024	\$0.21	1,083,333	(1,076,111)	-	-	7,222
18/10/2021	18/10/2024	\$0.21	1,500,000	(1,490,000)	-	-	10,000
			<u>14,583,333</u>	<u>(14,486,111)</u>	<u>-</u>	<u>(80,000)</u>	<u>17,222</u>
Weighted average exercise price			\$0.20		\$0.00	\$0.19	\$0.21

2022

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
12/11/2020	31/10/2022	\$0.20	8,000,000	-	-	-	8,000,000
12/11/2020	31/10/2022	\$0.18	4,000,000	-	-	-	4,000,000
25/06/2021	24/06/2024	\$0.21	1,083,333	-	-	-	1,083,333
18/10/2021	18/10/2024	\$0.21	-	1,500,000	-	-	1,500,000
			<u>13,083,333</u>	<u>1,500,000</u>	<u>-</u>	<u>-</u>	<u>14,583,333</u>
Weighted average exercise price			\$0.19	\$0.21	\$0.00	\$0.00	\$0.20

The weighted average remaining contractual life of options outstanding at the end of the financial year was 1.17 years (2022: 4.96 years).

Accounting policy for share-based payments

Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Consolidated Entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

Note 34. Share-based payments (continued)

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying the Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period.
- from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the Consolidated Entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Consolidated Entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

Medlab Clinical Limited
Directors' declaration
30 June 2023


In the directors' opinion:

- the attached financial statements and notes comply with the *Corporations Act 2001*, the Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the Consolidated Entity's financial position as at 30 June 2023 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

The directors have been given the declarations required by section 295A of the *Corporations Act 2001*.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the *Corporations Act 2001*.

On behalf of the directors



M Hudson
Director

23 April 2024
Sydney



**INDEPENDENT AUDITOR'S REPORT TO THE OWNERS OF
MEDLAB CLINICAL LIMITED AND CONTROLLED ENTITIES
ABN 51 169 149 071**

Report on the Financial Report

Opinion

We have audited the financial report of Medlab Clinical Limited (the Company) and its controlled entities (the Group), which comprises the consolidated statement of financial position as at 30 June 2023, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and the directors' declaration.

In our opinion the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- a. giving a true and fair view of the Group's financial position as at 30 June 2023 and of its financial performance for the year then ended; and
- b. complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

The financial report also complies with the International Financial Reporting Standards as disclosed in Note 1.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110: *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Group, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter on Going Concern

We draw your attention to Note 1 on going concern in the financial report, which indicates that the consolidated entity incurred a loss of \$6,433,297 after income tax (2022: \$7,228,814 net loss) and net cash outflows from operating activities of \$5,470,015 (2022: \$9,267,533 net cash outflows). The ability of the consolidated entity to continue as a going concern is principally dependent upon the execution of a binding agreement in respect of a new opportunity. The Company is in discussions to obtain a strategic minerals business and anticipates this would include a capital raise of \$5M to acquire the asset and fund working capital. Along with other matters set forth in Note 1 that indicate that a material uncertainty exists that may cast doubt of the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.



Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report for the year ended 30 June 2023. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matter	How Our Audit Addressed the Key Audit Matter
<p>Going Concern</p> <p>Following operating losses, there is a heightened degree of judgement as to the Group's ability to continue as a going concern through the assessment period.</p> <p>Accordingly, we considered the appropriateness of the going concern assumption, the question as to whether there is a material uncertainty and the adequacy of management's disclosure to be a key risk.</p>	<p>We have challenged the key assumptions by management in their going concern assessment.</p> <p>This included an assessment of the Group's cash position and cashflow following year end and obtaining additional information in support of statements made in their note on going concern.</p>

There were no restrictions on our reporting of Key Audit Matters.

Information Other than the Financial Report and Auditor's Report Thereon

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2023, but does not include the financial report and our auditor's report thereon. Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Group are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.



Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the financial report. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on the Remuneration Report

We have audited the remuneration report included in the directors' report for the year ended 30 June 2023.

In our opinion, the remuneration report of Medlab Clinical Limited for the year ended 30 June 2023 complies with s 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Group are responsible for the preparation and presentation of the remuneration report in accordance with s 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the remuneration report, based on our audit conducted in accordance with Australian Auditing Standards.

MNSA PTY LTD

MNSA Pty Ltd

Mark Schiliro

Director

Sydney

Dated this 23rd of April 2024

Medlab Clinical Limited
Shareholder information
30 June 2023

The shareholder information set out below was applicable as at [DATE].

Equity security holders

Unquoted equity securities

There are no unquoted equity securities.

Substantial holders

There are no substantial holders in the Company.

Voting rights

The voting rights attached to ordinary shares are set out below:

Ordinary shares

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

There are no other classes of equity securities.

Medlab Clinical Limited
Corporate directory
30 June 2023

Directors	M Hudson - Non-Executive Chairman E Tan - Non-Executive Director T Walker - Non-Executive Director
Company secretary	Kerem Kaya
Registered office and principal place of business	Nova Legal Corporate Lawyers Level 2 50 Kings Park Road West Perth WA 6005
Share register	Automic Group Level 5 191 St Georges Terrace Perth WA 6000
Auditor	MNSA Pty Limited 283 George Street Sydney NSW 2000
Patent Attorneys	Davies Collison Cave 255 Elizabeth Street Sydney NSW 2000
Bankers	Commonwealth Bank Australia Limited 48 Martin Place Sydney NSW 2000
Stock exchange listing	Medlab Clinical Limited shares are listed on the Australian Securities Exchange (ASX code: MDC)
Website	www.medlab.co